Huntington's Disease Treatment

Details Huntington's Disease Treatment Huntington's Disease Treatment

2007-05-22

2007-05-22

Hayes, Robert C. (Department: 1649)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C435S007100

Reexamination Certificate

active

10843209

ABSTRACT:
A method of identifying a 5′AMP-activated protein kinase inhibitor for treating a neurodegenerative disease. Disclosed are a method and a packaged product for treating a neurodegenerative disease. Also disclosed is a method for treating a 5′AMP-activated protein kinase-related disease and a related packaged product.

REFERENCES:
patent: 4968697 (1990-11-01), Hutchison
patent: 5714460 (1998-02-01), Gluckman et al.
patent: 6124125 (2000-09-01), Kemp et al.
patent: 2004/0229837 (2004-11-01), Chern et al.
Gamble J, Lopaschuk GD. 1997. Insulin inhibition of 5′ adenosine . . . Metabolism 46(11):1270-1274.
Moore, F. et al. 1991. Evidence that AMP triggers . . . Eur J Biochem 199:691-697.
Bonelli, RM and Hofmann, P. 2004. A review of the treatment options for Huntington's disease. Exert Opin. Pharacother. 5(4):767-776.
Popoli, P, Pezzola, A, Reggio, R, Caporali, MG, and de Carolis, AS. 1994. CGS21680 anatagonizes motor activity . . . European Journal of Pharmacology 257:R5-R6.
Chern, Y. and Lee, Y-C. 2004. Application of CGS21680 and other agonists . . . http://www.sinica.edu.tw/˜ip/Technology—e/12—MedBio/12A-911101—e.htm. Last updated Apr. 26, 2004.
Hawley, SA et al. 5′-AMP activates the AMP-activated protein kinase cascade . . . 1995. J Biol Chem 45:27168-27191.
Davies, SP et al. 1990. Location and function of three sites . . . Eur J Biochem 187:183-190.
Chen, Z-P et al. 1999. AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS letters 443:285-289.
Jarvis et al. 1989. [3H]CGS21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rate brain. J Pharm Exp Therap 251(3):888-893.
Suh YH et al. 2002. Pharmacological Reviews 54:469-525.
Shaw RJ et al. 2004. PNAS 101:3329-3335.
Sigma Catalog 2000-2001. p. 229.
Sigma Catalog 1994. p. 582.
Gamble, J. et al. 1997. Metabolism 46:1270-1274.
Feigin et al. 2002. Curr Opin Neurol 15:483-489.
Senatorov et al. 2004. Mol Psychiatry 9:371-385.
Mazumder et al., 2003. Trends in Biochemical Sciences 28:91-98.
Hsiao-Chun Cheng et al. “Essential Role of cAMP-response Element-binding Protein Activation by A2AAdenosine Receptors in Rescuing the Nerve Growth Factor-induced Neurite Outgrowth Impaired by Blockage of the MAPK Cascade”. Journal of Biological Chemistry 277(37):33930-33942, 2002.
Wenzhen Duan et al. “Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice”, PNAS 100(5):2911-2916, Mar. 4, 2003.
Robert J. Ferrante et al. “Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease”. Journal of Neuroscience 20(12):4389-4397, Jun. 15, 2000.
Mari Garseth et al. “Proton Magnetic Resonance Spectorscopy of Cerebrospinal Fluid in Neurodegenerative Disease: Indication of Glial Energy Impairment in Huntington Chorea, but Not Parkinson Disease”. Journal of Neuroscience Research 60:779-782, 2000.
Nai-Kuei Huang et al. “Activation of Protein Kinase A and Atopical Protein Kinase C and A2ADeprivation in PC12 Cells”. Journal of Biological Chemistry 276(17):13838-13846, 2001.
Marc S. Hurlbert et al. “Mice Transgenic for an Expanded CAG Repeat in the Huntington's Disease Gene Develop Diabetes”. Diabetes 48:649-651, Mar. 1999.
Bruce G. Jenkins et al. “Nonlinear Decrease over Time in N-Acetyl Aspartate Levels in the Absence of Neuronal Loss and Increases in Glutamine and Glucose in Transgenic Huntington's Disease Mice”. Journal of Neurochemistry 74:2108-2119, 2000.
Guy A. Rutter et al. “Role of 5′-AMP-activated protein kinase (AMPK) in mammalian glucose homoeostatis”. Journal of Biochemistry 375:1-16, 2003.
W. W. Winder. “Energy-sensing and signaling by AMP-activated protein kinase in skeletal muscle”. J. Appl. Physiol. 91:1017-1028, 2001.
Gabriela da Silva Xavier et al. “Role of AMP-activated protein kinase in glucose-stimulated insulin secretion and preproinsulin gene expression”. Journal of Biochemistry 371:761-774, 2003.

Affiliated with

Also associated with

Rating

Huntington's Disease Treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Huntington's Disease Treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Huntington's Disease Treatment will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3784790